- NASDAQ: INO is set to kick off the new week above $30, resuming its rise.
- Inovio Pharmaceuticals is due to publish preliminary safety and immunogenicity figures for its COVID-19 vaccine shortly.
- Analyst recommendations that have triggered the profit-taking are still in play.
NASDAQ: INO has been attracting attention since the coronavirus crisis erupted and especially in recent days after announcing a fat contract with the Department of Defense (DOD).
The $71 million contract with the federal government will help Inovio fund its efforts for developing a vaccine for COVID-19. The deal forbids the firm to sell its Cellectra 3PSP prototype device to any other entity at a lower price.
Details about progress around these immunization efforts – the preliminary safety and immunogenicity figures –are due out by the end of the month, which concludes on Tuesday.
Inovio Pharmaceuticals Stock
After surging above $30 – and completing a nine-fold leap – profit-takers came along and sold off NASDAQ: INO shares, which closed at $29.98 on Friday after hitting a new 52-week peak at $33.79.
One of the downside drivers came from Stephan Willey, an analyst with Stifel Nicolaus who cut the Inovio's rating from buy to hold. He said that investors see the Plymouth Meeting, Pennsylvania based firm's shares as "less palatable" to investors. His target is $24, below the current price.
That will come to the test soon enough. Apart from the publication of the immunogenicity data, other factors impacting NASDAQ: INO are end-of-quarter flows, which always cause high volatility in markets.
On the other hand, the broader equity market remains concerned about the rapid spread of COVID-19 in America, with California and Florida ordering the closure of certain activities, record infections in Arizona and Georgia, and fears about hospital capacity in various cities in Texas. Growing concerns may push S&P 500 investors away from stocks that depend on consumption and into ones focusing on the disease, such as Inovio Pharmaceuticals
Our latest:
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD ticks lower toward 0.6200 after Australian Nov inflation data
AUD/USD remains pressured toward 0.6200 following the release of Australian consumer inflation figures, which showed a slowing in the trimmed mean annual CPI , boosting the odds for an April RBA rate cut. Meanwhile, US-China trade war fears and a softer risk tone add to the weight on the pair.
USD/JPY steadies at around 158.00, Fed Minutes awaited
USD/JPY holds steady at atound the 158.00 mark early Wednesday amid uncertainty over further BoJ rate hikes. Further, the Fed's hawkish shift, the recent surge in the US bond yields and a bullish US Dollar support the currency pair, though Trump trade risks cap gains. US ADP data and Fed Minutes eyed.
Gold price consolidates around $2,650 area as traders await FOMC Minutes
Gold price struggles to attract buyers amid the Fed’s hawkish stance and elevated US bond yields. Trade war fears and geopolitical risks lend support to the XAU/USD amid a modest USD downtick. Investors look to the US macro data and FOMC meeting Minutes for some meaningful impetus.
Top 3 Price Prediction Bitcoin, Ethereum, Ripple: Over $560 million in liquidation
Bitcoin hovers around $97,000 on Wednesday after declining more than 5% the previous day. Ethereum and Ripple follow in BTC’s footsteps and decline 8.3% and 6.15% respectively.
Five fundamentals for the week: Nonfarm Payrolls to keep traders on edge in first full week of 2025 Premium
Did the US economy enjoy a strong finish to 2024? That is the question in the first full week of trading in 2025. The all-important NFP stand out, but a look at the Federal Reserve and the Chinese economy is also of interest.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.